Jean Bergeron is a physician acting as consultant and clinical scientist at the, Endocrinology and Nephrology Research Unit, Centre de recherche du CHU de Québec – Université Laval, as well as Professor at the Molecular Biology, Medical Biochimistry and Pathology Department, Faculty of Medicine, Laval University. He is member of the Medical Biochimistry Unit (Department of Laboratory Medicine) and chief of the Lipid clinic (Department of Medicine) of the CHU de Québec-Université Laval. He is also Secretary for the Société Québécoise de Lipidologie, Nutrition et Métabolisme (SQLNM), a scientific society from which he received in 2012 a recognition award, Le prix des Fondateurs Jean Davignon et Paul-J. Lupien, for his outstanding contribution in the field of lipidology. As specialist in laboratory medicine and lipidology, he supervises the CHU de Québec – Laval University clinical lipid laboratory performing lipoprotein, lipid and gene analyses.


Interest in clinical research

During his career, he has been dedicated to a better understanding of clinical and biological expressions of primary and secondary hyperlipidemia. He has also participated in the development and application of up to date lipid guidelines for clinicians and contributed to the characterization of new metabolic markers related to atherosclerosis and heart disease. He participated to numerous clinical trials using statins and new emergent therapies in lipoprotein metabolism.


Actual clinical research

More recently, he is involved in research on statin-generated myopathy, including identification of blood or genetic markers related to statin side effect and development of clinical tools for a better support to patients suffering from this condition. He is involved in the Canadian Familial Hypercholesterolemia registry. Finally, he is principal investigator in several clinical trials using PCSK9 inhibitors, anti-sense oligonucleotides, ANGPTL-3 inhibitors, and in some cases, gene therapy for very severe hypercholesterolemia or patients at very high CV risk for premature atherosclerotic heart disease.


2705, boulevard Laurier
Québec, Québec
Canada G1V 4G2

Latest news

Data not available

224 entries « 23 of 23 »

Turcotte GE, Nadeau L, Forest JC, Douville P, Leclerc P, Bergeron J, De Laclos BF

A new rapid immunoinhibition pancreatic amylase assay: diagnostic value for pancreatitis.

Journal Article

Clin Biochem, 27 (2), pp. 133-9, 1994, ISSN: 0009-9120.

Abstract | Links:

Normand T, Bergeron J, Fernandez-Margallo T, Bharucha A, Ven Murthy MR, Julien P, Gagne C, Dionne C, De Braekeleer M, Ma R, et al.

Geographic distribution and genealogy of mutation 207 of the lipoprotein lipase gene in the French Canadian population of Quebec.

Journal Article

Hum Genet, 89 (6), pp. 671-5, 1992, ISSN: 0340-6717.

Abstract | Links:

Bergeron J, Normand T, Bharucha A, Ven Murthy MR, Julien P, Gagne C, Dionne C, De Braekeleer M, Brun D, Hayden MR, et al.

Prevalence, geographical distribution and genealogical investigations of mutation 188 of lipoprotein lipase gene in the French Canadian population of Quebec.

Journal Article

Clin Genet, 41 (4), pp. 206-10, 1992, ISSN: 0009-9163.

Abstract | Links:

Lavoie R, Bergeron J, Fruteau de Laclos B, Forest JC

Determination of free testosterone fraction of human serum by gel bead dialysis.

Journal Article

Clin Biochem, 22 (6), pp. 451-6, 1989, ISSN: 0009-9120.

Abstract | Links:

224 entries « 23 of 23 »
Signaler des ajouts ou des modifications

Recently finished projects

  • Homozygous familial hypercholesterolemia (HoFH) in Canada, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2019-12-01 to 2020-03-31
Data provided by the Université Laval research projects registery